Skip to main content
Clinical Trials/NCT02477384
NCT02477384
Completed
Not Applicable

Randomised Trial of 8mm Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Variceal Ligation Plus Propranolol for Prevention of Variceal Rebleeding

West China Hospital1 site in 1 country100 target enrollmentJune 2015

Overview

Phase
Not Applicable
Intervention
8mm-TIPS
Conditions
Portal Hypertension
Sponsor
West China Hospital
Enrollment
100
Locations
1
Primary Endpoint
Variceal rebleeding rate
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The aim of this study was to conduct a prospective randomized trial to compare TIPS with 8mm expanded polytetrafluoroethylene(ePTFE)-covered stents and endoscopic variceal ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding.

Detailed Description

For the prevention of recurrent esophageal variceal bleeding, previous clinical studies and meta-analysis show that patients treated with transjugular intrahepatic portosystemic shunt (TIPS) have lower rebleeding rates compared with endoscopic therapy. However, TIPS is associated with higher rates of portosystemic encephalopathy and does not show survival benefit. TIPS with a small-diameter may achieve sufficient portal decompression and reduce the incidence of hepatic encephalopathy. The aim of this study was to conduct a prospective randomized trial to compare TIPS with 8mm ePTFE-covered stents and endoscopic variceal ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding.

Registry
clinicaltrials.gov
Start Date
June 2015
End Date
July 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

luo xuefeng

MD

West China Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients who had bled from esophageal varices (≥5days and ≤28days)
  • Child-Pugh B or Child-Pugh C≤13

Exclusion Criteria

  • THE presence of gastric varices
  • Non-cirrhotic portal hypertension
  • Portal vein thrombosis
  • The history of hepatic encephalopathy
  • Total bilirubin ≥51.3 umol/L
  • Previous treatment of TIPS or surgery
  • Proven malignancy including hepatocellular carcinoma
  • Contraindications to TIPS、EVL or propranolol
  • End-stage renal disease under renal replacement therapy;
  • Cardiorespiratory failure

Arms & Interventions

8mm-TIPS

Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.

Intervention: 8mm-TIPS

8mm-TIPS

Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.

Intervention: 8mm ePTFE-covered stent

EVL plus propranolol

Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.

Intervention: Endoscopic variceal ligation

EVL plus propranolol

Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.

Intervention: Propranolol

Outcomes

Primary Outcomes

Variceal rebleeding rate

Time Frame: 3 years

Analysis

Secondary Outcomes

  • Number of participants with improving or worsening hepatic function(3 years)
  • The incidence of complications(3 years)
  • Hepatic encephalopathy rate(3 years)
  • Number of participants with improving or worsening quality of life(3 years)
  • TIPS dysfunction rate(3 years)
  • Mortality rate(3 years)

Study Sites (1)

Loading locations...

Similar Trials